Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 2, 2009, Pages 137-142

  Delongchamps, Nicolas B ^a,b   de la Roza, G ^a   Chandan, V ^a   Jones, R ^a   Threatte, G ^a   Jumbelic, M ^c   Haas, G P ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b René Descartes University ^*  (France)

^c Onondaga County Medical Examiner   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOPSY; BIOPSY TECHNIQUE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MICROFOCAL PROSTATE CANCER; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; AUTOPSY; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 67349173195     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.38     Document Type: Article

References (31)

1. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage midgration. J Urol 2005; 174: 1789-1793.
2. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60: 458.
3. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175: 907-912.
4. Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH et al. Management and survival of screendetected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006; 50: 473-482.
5. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 933-938.
6. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (T1c) prostate cancer. JAMA 1994; 271: 368-374.
7. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H et al Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 2407-2411.
8. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with T1c adenocarcinoma of the prostate. J Urol 1997; 157 2206-2209.
9. Noguchi M, Starney TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104-109.
10. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: Can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004; 64: 544-550.
11. Allan RW, Sanderson H, Epstein JI. Correlation of minute (05mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: Role of prostate specific antigen density. J Urol 2003; 170: 370-372.
12. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA. Micro-focal cancer: A comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005; 48: 895-899.
13. Wise AM, Stamey TA, Mc Neal JE, Claytoin JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264.
14. Haas GP, Delongchamps NB, Jones RF, Chanclan V, Serio AM, Vickers AJ et al. Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007; 99 1484-1489.
15. Troncoso P, Babaian RJ, Ro JY, Grignon DJ, von Eschenbach AC, Ayala AG. Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology 1989; 34: 52-56.
16. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) concensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
17. Noguchi M, Stamey TA, McNeal JE, Yemoto CE. Assessment of morphometric measurements of prostate carcinoma volume. Cancer 2000; 89: 1056-1064.
18. Schned AR, Wheeler KJ, Hodorowski CA, Heaney JA, Ernstoff MS, Amdur RJ et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol 1996; 20: 1501-1506.
19. McNeal JE, Bostwick DG, Kindrachuck RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1 60-63.
20. Lowe BA, Listrom MB. Incidental carcinoma of the prostate: An analysis of the predictors of progression. J Urol 1988; 140: 1340-1344.
21. Ravery V, Chastang C, Toublanc M, Boccon-Gibod L, Delmas V, Boccon-Gibod L. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol 2000; 37: 449-455.
22. Algaba F, Arce, Y, Oliver A, Barandica C, Santaularia JM, Montanés R. Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy. Eur Urol 2005; 48: 566-571.
23. Montironi R, Vela-Navarrete R, Lopez-Beltran A, Mazzucchelli R, Bono A. 2005 update on pathology of prostate biopsies with cancer. Eur Urol 2006; 49: 441-447.
24. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review. J Urol 2006; 175: 1605-1612.
25. Boccon-Gibod LM, Delongchamps NB, Toublanc M, Boccon-Gibod LA, Ravery V. Prostate saturation biopsy in the reevaluation of microfocal prostate cancer. J Urol 2006; 176: 961-963.
26. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66: 356-360.
27. Koppie TM, Bianco Jr FJ, Kuroiwa K, Reuter VE, Guillonneau B, Eastham JA et al. The clinical features of anterior prostate cancers. BJU Int 2006; 98: 1167-1171.
28. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: The role of transperitoneal 3-dimensional pathologic mapping of the prostate. A 4 year experience. Urology 2007; 70: 27-35.
29. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288-294.
30. Iguchi T, Wang CY, Delongchamps NB, Sunheimer R, Nakatani T, de la Roza G et al. Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology 2008; [E-pub ahead of print].
31. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G et al. Evaluation of prostatitis in autopsied prostates: Is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736-1740.